Earnings

Adjusted EBITDA attributable to MPLX was USD 1.859 billion against USD 1.766 billion, and distributable cash flow rose to USD 1.537 billion from USD 1.468 billion. The partnership returned about USD 1.1 billion ofCapitalto unitholders.

Adjusted diluted EPS excludes USD 0.07 per share of intangible amortization tied to the Bachan'sAcquisitionin the current quarter and USD 0.03 per share of restructuring andImpairmentcharges in the prior year quarter. Excluding prior year sales under a temporarySupplyagreement, adjusted consolidated net sales fell 0.3%.

The net increase in netAssetsfrom operations was USD 16.0 million, or USD 0.32 per share, compared with USD 18.7 million, or USD 0.38, a year earlier. Net realized losses of USD 4.0 million and a net unrealized gain of USD 1.2 million left total …

Sealing Technologies sales rose 20.5% to USD 214.7 million, or 11.6% excluding currency and USD 15.1 million from acquisitions completed in the fourth quarter of 2025. Pricing and mix contributed USD 6.0 million, and strength in space, general industrial and compositional analysis applications more …

The company attributed the operational revenue decrease of USD 57 million to lower COVID-19 product, Prevnar family and other revenues, largely offset by growth in Eliquis, Padcev, the Vyndaqel family, Nurtec ODT/Vydura and Lorbrena. Eliquis revenue rose to USD 2.523 billion from USD 2.015 …

Revenues fell on lower strategic advisory, restructuring and privateCapitalsolutions revenues, partly offset by higher primary fundraising revenues. Adjusted compensation and benefits expense dropped 15% to USD 256.1 million, or 66.5% of revenues versus 67.5%, on lower revenues and a lower accrual rate. Adjusted non-compensation …

The company attributed the increase mainly to higher customer usage and growth and to weather, partly offset by higherDepreciationand amortization, higher interest charges and lower other income. Nine month diluted EPS was USD 5.20 against USD 4.93.